Events
-
-
-
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
-
ASCO 2026: Lancet Commission predict shortfall of 100 million cancer care workers by 2050
-
ASCO 2026: Phase 3 PEAK study could usher in new second-line therapy for GIST
-
ASCO 2026: Personalised vaccine boosts immune activity against brain cancer
-
ASCO 2026: GLP-1s may reduce metastatic progression of certain obesity-related cancers
-
ASCO 2026: Yoga may help cancer survivors sleep better and reduce anxiety, fatigue
-
-
Pesticides and cancer: A study reveals the biological mechanisms behind an environmental health risk
A new scientific study, published in Nature Health, reveals a strong link between exposure to agricultural pesticides…
Tiny sensors with the power to detect cancer
Microscopic sensors that are as thin as a strand of hair but capable of taking…
The next leap for AI scribes provides eyes in the clinic
The introduction of vision-enabled artificial intelligence (AI) to medical scribes – the recording devices used…
EBCC 2026: Tumour DNA circulating in patients’ blood after pre-surgery treatments predicts whether breast cancer will return
- EBCC 2026: Early results from a trial of active surveillance for low-risk DCIS are ‘reassuring’
- EBCC15: Elinzanetant reduces severity and frequency of hot flushes and night sweats, regardless of type of hormone treatment breast cancer patients receive
- EBCC15: Breast cancer recurrence remains low, even after ten years, with radiotherapy tailored to patient’s individual risk
Microplastics discovered in prostate tumours
- Randomised trial finds drug therapy reduces hot flashes during prostate cancer treatment
- Niraparib and abiraterone acetate dual action tablet receives CHMP positive opinion for BRCA 1/2-mutated metastatic hormone-sensitive prostate cancer
- Leading UK cancer charities team up to tackle the spread of breast and prostate cancers to the bones
S3E1 The Oncology Journal Club: ASCO GI Highlights 2025
Welcome to Episode 1 of the Third Series of The Oncology Journal Club! Our Hosts Professor Craig Underhill and Professor Christopher Jackson are joined by Professor Chris Karapetis to unpack the ASCO GI 2025 meeting.
Muscle weakness in cancer survivors may be caused by treatable weakness in blood vessels – new research
Jalees Rehman, University of Illinois Chicago Tumours can destroy the blood vessels of muscles even when the muscles are nowhere…
JOIN THE ONCOLOGY NETWORK
If you would like even more free news articles, access to our exclusive HCP only content including the latest podcasts from The Oncology Podcast and our Industry Partner Podcasts (including links to all papers and show notes), along with all our other resources, head over to The Oncology Network and sign up - FREE forever for HCPs only.